This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
Leukemia Open Access 31 January 2024
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765–3776.
Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol 2016; 34: 2988–2996.
Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R et al. Combined treatment with lenalidomide and epoetinalfa in lower-risk patients with myelodysplastic syndrome. Blood 2012; 120: 3419–3424.
Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia 2016; 30: 897–905.
Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008; 5: e35.
Chesnais V, Renneville A, Toma A, Lambert J, Passet M, Dumont F et al. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. Blood 2016; 127: 749–760.
Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 2015; 523: 183–188.
Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA et al. Lenalidomide stabilizes the erythropoietin receptor by inhibiting the E3 ubiquitin ligase RNF41. Cancer Res 2016; 76: 3531–3540.
McDaniel JM, Zou JX, Fulp W, Chen DT, List AF, Epling-Burnette PK . Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia 2012; 26: 1425–1429.
Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117: 1605–1613.
Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 2016; 17: 218.
Linton PJ, Dorshkind K . Age-related changes in lymphocyte development and function. Nat Immunol 2004; 5: 133–139.
Sternberg A, Killick S, Littlewood T, Hatton C, Peniket A, Seidl T et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005; 106: 2982–2991.
Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, Bontkes HJ . Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 2011; 153: 568–581.
Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841–851.
Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis JH et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006; 20: 463–470.
Acknowledgements
We thank A Renneville, C Preudhomme (Lille), O Wagner-Ballon (Créteil) and E Solary (Villejuif) for helpful discussion, S Baulande from ICGex NGS platform of the Institut Curie and investigators of the Groupe Francophone des Myélodysplasies. This study received a research grant from Celgene and was conducted by two teams labeled by the SIRIC Cancer Research for PErsonalized Medicine CARPEM. OK received a CARPEM fellowship grant.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Kerdivel, G., Chesnais, V., Becht, E. et al. Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling. Leukemia 32, 558–562 (2018). https://doi.org/10.1038/leu.2017.305
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.305